Systematic Review: Case-Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding Events Among Patients Treated for Venous Thromboembolism
The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Case-fatality rates are important for assessing the risks and benefits of anticoagulation in patients with venous thromboembolism (VTE). PURPOSE: To summarize case-fatality rates of recurrent VTE and major bleeding events during anticoagulation and recurrent VTE after anticoagulation. DATA SOURCES: MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, and all evidence-based medicine reviews in the Ovid interface through the second quarter of 2008. STUDY SELECTION: 69 articles (13 prospective cohort studies and 56 randomized, controlled trials) that reported on patients with symptomatic VTE who received anticoagulation therapy for at least 3 months and on the rate of fatal recurrent VTE and fatal major bleeding. DATA EXTRACTION: Two reviewers independently extracted data onto standardized forms. DATA SYNTHESIS: During the initial 3 months of anticoagulation, the rate of recurrent fatal VTE was 0.4% (95% CI, 0.3% to 0.6%), with a case-fatality rate of 11.3% (CI, 8.0% to 15.2%). The rate of fatal major bleeding events was 0.2% (CI, 0.1% to 0.3%), with a case-fatality rate of 11.3% (CI, 7.5% to 15.9%). After anticoagulation, the rate of fatal recurrent VTE was 0.3 per 100 patient-years (CI, 0.1% to 0.4%), with a case-fatality rate of 3.6% (CI, 1.9% to 5.7%). LIMITATIONS: Estimates come from heterogeneous trial and cohort populations and are not derived from patient-level longitudinal data. Differences in case-fatality rates during and after anticoagulation may be attributable to unmeasured patient characteristics. CONCLUSION: The case-fatality rates of recurrent VTE and major bleeding events are similar during the initial period of VTE treatment. The case-fatality rate of recurrent VTE decreases after completion of the initial period of anticoagulation. When combined with absolute rates of recurrent VTE and major bleeding events, case-fatality rates provide clinicians with a surrogate measure of mortality to balance the risks and benefits of anticoagulant therapy in patients with VTE. PRIMARY FUNDING SOURCE: Canadian Institute for Health Research and Heart and Stroke Foundation of Ontario.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a meta-analysis of 13 prospective cohort studies and 56 randomized trials 98 in VTE patients showing a 2.1% risk for major bleeding during a 6-month treatment with anticoagulants.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [98]
In the citing paper
“In populations with a low risk for bleeding, 98 the use of a longer course, instead of a shorter course, of anticoagulation may lead to an increase of 10 more bleeding events per 1000 patients (95% CI, 5 fewer to 36 more; moderate-certainty evidence).”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [98]
In the citing paper
“In patient populations with any indication for anticoagulation and/or aspirin, 98 the use of anticoagulation with aspirin relative to anticoagulation alone led to an increase of 5 more major bleeding events per 1000 patients (95% CI, 2 fewer to 15 more; very-low-certainty evidence).”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [98]
In the citing paper
“reported 3.6% (1.9% to 5.7%) in a previous study of patients with VTE.40”
In the citing paper
“This case fatality rate is similar to the reported 3.6% (1.9% to 5.7%) in a previous study of patients with VTE.40”
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763 · cited 1×
“An I(2) value less than 25% was considered low-level heterogeneity, 25% to 50% was moderate-level, and greater than 50% was highlevel (8).”
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048 · cited 1×
“Thirty-two (57%) and 36 (64%) of the 56 RCTs reported adequate sequence generation and allocation concealment (4).”
(2014) · Medical Entomology and Zoology · Cited by 17,633
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Levine, M., Gent, M., Hirsh, J., Leclerc, J., Anderson, D., Weitz, J., Ginsberg, J., Turpie, A. G., Demers, C., Kovacs, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341101 · Cited by 1,192 · cited 3×
“Sequence Generation Allocation Concealment Blinding Incomplete Outcome Data Addressed Free of Selective Outcome Reporting Free of Other Bias Bratt et al, 1990 (9) Unclear Unclear No Unclear Unclear Yes European study, 1991 (10) Unclear Unclear No Yes Yes Yes Brandjes et al, 1992 (11) Unclear Unclear Yes Yes Yes Yes Hu…”
Koopman, M. M. W., Prandoni, P., Piovella, F., Ockelford, P. A., Brandjes, D. P. M., van der Meer, J., Gallus, A. S., Simonneau, G., Chesterman, C. H., Prins, M. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341102 · Cited by 1,111 · cited 2×
“Sequence Generation Allocation Concealment Blinding Incomplete Outcome Data Addressed Free of Selective Outcome Reporting Free of Other Bias Bratt et al, 1990 (9) Unclear Unclear No Unclear Unclear Yes European study, 1991 (10) Unclear Unclear No Yes Yes Yes Brandjes et al, 1992 (11) Unclear Unclear Yes Yes Yes Yes Hu…”
Schulman, S., Rhedin, A.-S., Lindmarker, P., Carlsson, A., Lärfars, G., Nicol, P., Loogna, E., Svensson, E., Ljungberg, B., Walter, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506223322501 · Cited by 932
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa035451 · Cited by 887 · cited 3×
“…al, 2001 (49) Yes Yes No Yes Yes Yes Findik et al, 2002 (50) Unclear Unclear No Yes Yes Yes Beckman et al, 2003 (51) Unclear Unclear No Yes Yes Yes Büller et al, 2003 (53) Yes Yes No Yes Yes Yes Kakkar et al, 2003 (54) Unclear Yes No Yes Yes Yes Kovacs et al, 2003 (55) Yes Yes Yes Unclear Yes…”
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808 · cited 3×
“…2003 (55) Yes Yes Yes Unclear Yes Yes Pérez de Llano et al, 2003 (56) Unclear Unclear No Yes Yes Yes Riess et al, 2003 (57) Yes Yes No Yes Yes Yes Ridker et al, 2003 (58) Yes Yes Yes Unclear Yes Yes Schulman et al, 2003 (59) Yes Yes Yes Yes Yes Yes Büller et al, 2004 (60) Yes Yes Yes Yes Yes…”
Low-Molecular-Weight Heparin in the Treatment of Patients with Venous Thromboembolism
(1997) · New England Journal of Medicine · doi:10.1056/nejm199709043371001 · Cited by 784
Research works printed but not linked: 7
- Miller JJ, 1978, The American Statistician, 32, 138
- Grau E, 1998, Haematologica, 83, 438
- Kirchmaier CM, 1998, Int Angiol, 17, 135
- Leroyer C, 1998, Haemostasis, 28, 70
- Zidane M, 2006, Haematologica, 91, 1052
- van Der Heijden JF, 2000, Cochrane Database Syst Rev, CD002001
- van Dongen CJ, 2005, Cochrane Database Syst Rev, CD003074
Cited by
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Konstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.-J., Harjola, V.-P., Huisman, M. V., Humbert, M., Jennings, C. S., Jiménez, D., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz405 · Cited by 4,916
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Self-citationKonstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.-J., Harjola, V.-P., Huisman, M. V., Humbert, M., Jennings, C. S., Jiménez, D., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01647-2019 · Cited by 1,619
“Moreover, bedside CUS can detect proximal DVT.”
BackgroundOrtel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001830 · Cited by 1,489
Metadata
- Authors
- Carrier, M., Le Gal, G., Wells, P. S., & Rodger, M. A.
- Affiliations
- University of Ottawa (CA)
- From University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada, and Brest University Hospital, Brest, France.
- Corresponding author
- Carrier, Marc
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2010-05-04
- Volume
- 152
- Issue
- 9
- Pages
- 578-589
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2076621544
- Cited by
- 473
- References
- 85
- Citations by year
- 2026: 10 · 2025: 20 · 2024: 21 · 2023: 16 · 2022: 19 · 2021: 24 · 2020: 37 · 2019: 34 · 2018: 33 · 2017: 48 · 2016: 43 · 2015: 26 · 2014: 30 · 2013: 39 · 2012: 36
- FWCI
- 7.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- venous thromboembolism, recurrent venous thromboembolism, case fatality rate, major bleeding, fatal bleeding, anticoagulation, mortality, risk-benefit assessment, anticoagulation duration, pulmonary embolism, deep vein thrombosis, bleeding risk stratification, risk prediction model
- MeSH terms
- Anticoagulants, Hemorrhage, Humans, Recurrence, Risk Assessment, Venous Thromboembolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systematic Review: Case-Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding Events Among Patients Treated for Venous Thromboembolism. https://app.cochat.ai/papers/10.7326/0003-4819-152-9-201005040-00008
- The paper
- Carrier, M., Le Gal, G., Wells, P. S., & Rodger, M. A. (2010). Systematic Review: Case-Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding Events Among Patients Treated for Venous Thromboembolism. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-152-9-201005040-00008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.